Effect of prostaglandin E2, lipopolysaccharide, IFN-γ and cytokines on the generation and function of fast-DC

Cytotherapy

Volumn 7, Issue 2, 2005, Pages 195-202

  Alldawi, Louie ^a   Takahashi, M ^a   Narita, M ^a   Ayres, F ^a   Tsukada, N ^a   Osman, Y ^a   Furukawa, T ^b   Aizawa, Y ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Fast DC; T cell proliferation

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 14; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PROSTAGLANDIN E2; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 6; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; OXYTOCIC AGENT;

ANTIGEN SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MOLECULAR STABILITY; MONOCYTE; NORMAL HUMAN; PHENOTYPE; T LYMPHOCYTE; TIME MANAGEMENT; CELL CULTURE; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; HUMANS; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; OXYTOCICS;

EID: 21044434213     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240510018127     Document Type: Article

References (21)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity, Nature 1998;392:245-52.
2. Obermaier B, Dauer M, Herten J et al. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proc 2003;5:197-203.
3. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003;170:4069-76.
4. Lee AW, Truong T, Bickham K et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002;(suppl 4):A8-22.
5. Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-98.
6. Thurner B, Haendle I, Roder C et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
7. + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165: 3492-6.
8. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
9. Takahashi A, Kono K, Ichihara F et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatorv cytokines. Cancer Immunol Immunother 2004;53(6)543-50.
10. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by gratinulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by rumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
11. Palucka KA, Taquet N, Sanchez-Chapuis F et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 1998;160:4587-95.
12. Hausser G, Ludewig B, Gelderblom H et al. Monocyte-derived dendritic cells represent a transient stage of differentiation in the myeloid lineage. Immunobiology 1997;197:534-42.
13. Langenkamp A, Casorati G, Garavaglia C et al. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 2002;32:2046-54.
14. Kalinski P, Schuitemaker JH, Hilkens CM et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999;162:3231-6.
15. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998;161:2804-9.
16. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10 which down-regulates dendritic cell functions. J Immunol 2002;168:2255-63.
17. Scandella E, Men Y, Gillessen S et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100:1354-61.
18. Scandella E, Men Y, Legler DF et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells require prostaglandin E2. Blood 2004;103:1595-601.
19. Chen T, Guo J, Yang M et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 2004;103:413-21.
20. Weinmann O, Gutzmer R, Zwirner J et al. Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2. Immunology 2003;110:458-65.
21. Sallusto F, Schaerli P, Loetscher P et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-9.